Drug intelligence / Profile preview

Sorbitol + phenylephrine

Development stage
Unknown
Lead developer
Ferring Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Sorbitol + phenylephrine is a combination of two agents commonly found in over-the-counter and prescription medications for symptomatic relief of nasal congestion and related upper respiratory symptoms. Sorbitol is a sugar alcohol (polyol) used primarily as a sweetener, humectant, or laxative in pharmaceutical formulations[4][5]. Phenylephrine is an alpha-1 adrenergic receptor agonist that acts as a decongestant by causing vasoconstriction of blood vessels in the nasal mucosa, thereby reducing swelling and congestion[1][2][6]. The combination may be present in oral liquid preparations where sorbitol serves as an excipient to improve taste or texture while phenylephrine provides therapeutic action against nasal congestion. Phenylephrine’s mechanism involves selective stimulation of alpha-1 adrenergic receptors leading to vasoconstriction; it can also increase blood pressure when administered systemically[1]. Sorbitol itself does not have direct pharmacological activity on the respiratory tract but may contribute to gastrointestinal effects if consumed in significant quantities.

02

Targets

ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)

Beyond the preview

Go deeper on Sorbitol + phenylephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sorbitol + phenylephrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call